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Exploring the Scope of the Isothiourea-mediated 
Synthesis of Dihydropyridinones 
 
Pei-Pei Yeh, David S. B. Daniels, Charlene Fallan, Eoin Gould, Carmen Simal, 
James E. Taylor, Alexandra M. Z. Slawin and Andrew D. Smith* 
The exploration and expansion of the scope of the isothiourea-mediated synthesis of 
dihydropyridinones is presented. The use of ketimines derived from α,β-unsaturated γ-ketoesters as the 
Michael acceptor in a Michael addition / lactamisation cascade gives access to a range of 
dihydropyridinones with high enantioselectivity. The nature of the N-sulfonyl group present on the 
ketimine is extensively investigated, with further studies into derivatisation of the dihydropyridinone 
core also reported. 
Introduction  
The direct organocatalytic asymmetric functionalisation of 
readily available, bench-stable carboxylic acids1 towards value-
added products has received much attention since the seminal 
report by Romo and co-workers in 2001 on the intramolecular 
nucleophile-catalysed aldol / lactonisation (NCAL) reaction 
(Scheme 1).2 Further work from the Romo group has 
demonstrated the utility of ammonium and isothiouronium 
enolates generated from carboxylic acids in the stereoselective 
synthesis of β-lactones,3 including the application to the total 
synthesis of (+)-omphadiol3j 1 and (−)-curcumalactone 2 
(Scheme 1), amongst others.3l 
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Scheme 1 Romo and co-wokers’ intramolecular NCAL reaction
2
 and select 
examples of natural products accessed using this reaction.
3j,3l
 
We have previously explored the scope of the intramolecular 
reactions of ammonium and isothiouronium enolates,4 allowing 
access to dihydrobenzofurans,5 2H-indenes,5a THFs,5b as well 
as pyrrolidines.6 Intermolecular reactions have also been 
developed, with formal [2+2]- and [4+2]-cycloadditions 
between isothiouronium enolates and suitable electrophiles 
greatly expanding the range of valuable heterocyclic products 
that can be accessed directly from carboxylic acids. This has 
included dihydropyranones,5a,7 β-lactams,8 
dihydropyridinones,9 pyridines,10 2-pyrones11 and a variety of 
acyclic products from further derivatisation of the heterocyclic 
cores.12 
Our previous synthesis of dihydropyridinones reacted 
isothiouronium enolates generated from carboxylic acids with 
N-tosyl chalcone-derived ketimines in a Michael addition / 
lactamisation cascade (Scheme 2a).9 This afforded a range of 
dihydropyridinones in high yields and excellent 
stereoselectivity. In this methodology the N-tosyl substituent 
was employed exclusively in the ketimine Michael acceptor. 
Furthermore, the use of chalcones as the backbone of the 
ketimine, alongside the requirement for aryl or heteroaryl acetic 
acids, resulted in dihydropyridinones furnished with three 
(hetero)aryl substituents thereby constraining the scope of the 
hetercyclic products. To extend these studies, alternative 
ketimine backbones incorporating more versatile functional 
handles, whilst maintaining the reactivity of the Michael 
acceptor were explored. Herein we report the successful 
incorporation of ketimines derived from α,β-unsaturated γ-
ketoesters within this  
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Scheme 2 Organocatalytic synthesis of dihydropyridinones 
methodology,10,13 affording dihydropyridinone products 
containing ester substituents as functional handles (Scheme 2b). 
Extensive exploration of the sulfonyl substituent and the 
potential for derivatisation of the dihydropyridinone core is also 
described. 
Results and Discussion 
Optimisation 
Initial studies showed that α,β-unsaturated γ-ketimine ester 6 
was a competent electrophile for intermolecular Michael 
addition / lactamisation with the isothiouronium enolate 
generated from phenylacetic acid 5 after in situ formation of a 
mixed anhydride using pivaloyl chloride and base, and reaction 
with achiral isothiourea DHPB 7. This allows formation of 
dihydropyridinone 8 in 65% isolated yield as an 88:12 mixture 
of diastereoisomers (Scheme 3a). In contrast, the related but 
isomeric Michael acceptor 9 resulted in a ca. 1:1 mixture of 
diastereoisomers in a poorer yield (Scheme 3b).14  
 
With reactivity and diastereoselectivity confirmed with Michael 
acceptor 6, a screen of common chiral isothiourea Lewis bases 
3, 4 and 11 showed (−)-tetramisole·HCl 4 to be optimum in 
terms of both isolated yield and stereoselectivity (Table 1, 
entries 1-3). Examining the catalyst loading revealed that 
although increasing to 40 mol% 4 gave a higher isolated yield 
of 8, the diastereoselectivity suffered (entry 4). Conversely, 
lowering the loading to 10 mol% resulted in incomplete 
conversion of 6 even after extended reaction times (entry 5). 
Next, the activating agent for generation of the in situ formed 
mixed anhydride was examined, showing that pivaloyl chloride 
was the best choice  
 
Scheme 3 Initial investigations 
over a range of benzoyl chloride derivatives (entries 6-8). 
Tetramisole free base (entry 9) and excess i-Pr2NEt (1.2 eq., 
entry 10) were examined, resulting in a slight reduction of 
diastereoselectivity and yield, respectively. Increasing the 
amount of carboxylic acid and pivaloyl chloride to two 
equivalents led to consistently higher isolated yields in a short 
reaction time, even under the more operationally simple non-
anhydrous conditions of bench solvent and un-dried glassware 
(entries 11 and 12). Reducing the catalyst loading under these 
conditions was again found to be detrimental to the isolated 
yield of 8 (entry 13). The scalability of the reaction was 
examined with 5.0 mmol of 6 affording 1.48 g (3.2 mmol) of 8 
(entry 14) in near identical yield and stereoselectivity to that on 
0.2 mmol scale (cf. entry 12), demonstrated the ability of this 
methodology to deliver gram quantities of enantioenriched 
dihydropyridinones. 
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Table 1 Reaction Optimisationa 
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Entry LB (mol%) Activating 
Agent (eq.) 
time (h) yield (%)b dr (anti:syn)c / 
ee (anti, %)d 
1 4 (20) t-BuCOCl (1) 3 46 97:3 / 98 
2 11 (20) t-BuCOCl (1) 16 33 75:25 / 95 (ent) 
3 3 (20) t-BuCOCl (1) 16 28 >95:5 / 98 (ent) 
4 4 (40) t-BuCOCl (1) 3 75 93:7 / 98 
5 4 (10) t-BuCOCl (1) 24 38 97:3 / 98 
6 4 (20) PhCOCl (1) 3 32 91:9 / 90 
7 4 (20) PMPCOCle (1) 24 17 90:10 / 98 
8 4 (20) PNPCOClf (1) 3 29 83:17 / 94 
9g 4 (20) t-BuCOCl (1) 3 62 93:7 / 98 
10h 4 (20) t-BuCOCl (1) 3 31 98:2 / 98 
11i 4 (20) t-BuCOCl (2) 1 62 93:7 / 98 
12i,j 4 (20) t-BuCOCl (2) 1 65 92:8 / 98 
13i 4 (10) t-BuCOCl (2) 3 45 97:3 / 95 
14k 4 (20) t-BuCOCl (2) 1 64 92:8 / 98 
a Reaction Conditions: 5 (1 eq.), Activating agent (1 eq.), i-Pr2NEt (1 eq.), 
CH2Cl2; then 6 (1 eq.), LB, i-Pr2NEt (1 eq.); 
b Isolated yield; c Measured by 
1H NMR; d Measured by chiral HPLC; e PMP = 4-methoxyphenyl; f PNP = 4-
nitrophenyl; g Tetramisole free base was used; h i-Pr2NEt (1.2 eq.) was used. 
i 
5 (2 eq.), activating agent (2 eq.) and i-Pr2NEt (2 eq.) were used. 
j Bench-
grade solvents used;  k 5.0 mmol of 6. 
In an attempt to simplify the experimental procedure the 
possibility of using preformed homoanhydrides was explored 
(Scheme 4), with 2-phenylacetic anhydride 12 used in place of 
the combination of 2-phenylacetic acid and pivaloyl chloride. 
The purification of 8 was greatly simplified under this protocol, 
however lower diastereo- and enantioselectivity was observed 
with (−)-tetramisole·HCl 4. HyperBTM 11 performed better in 
terms of enantioselectivity at the lower loading of 5 mol %, 
although 60:40 dr was observed. This may be owing to in situ 
epimerisation of the dihydropyridinone product, a conjecture 
that is supported by the high ee observed for the syn-
diastereoisomer in this case. Therefore, the use of pre-activated 
homoanhydrides was not explored further. 
 
Scheme 4 Investigation of homoanhydride 12 
Exploration of the N-Sulfonyl Substituent 
Having optimised the model system, exploration of the scope 
and limitations of this process required a general synthetic route 
to a range of ketimines. Their synthesis was achieved either 
directly from commercially available ethyl 3-benzoylacrylate 
13 through TiCl4-mediated imine formation (Scheme 5a),
13,15 or 
efficiently in three steps from (+)-diethyl L-tartrate 15 via 
oxidative cleavage, Wittig reaction of the resulting aldehyde,16 
and imine formation using TiCl4 (Scheme 5b). In most cases 
the crude ketimines were purified through trituration and 
recrystallisation, thereby avoiding silica gel chromatography 
that leads to significant hydrolysis of these somewhat sensitive 
imines.17 
 
Scheme 5 Synthesis of N-sulfonyl ketimines 
Initially, the scope of the sulfonyl group was examined to probe 
the effect of varying the steric and electronic properties of the 
N-substituent on the Michael addition / lactamisation (Table 2). 
A range of different aryl groups was incorporated, including 
electron-donating tosyl 18 and SO2PMP 19, and electron-
withdrawing 4-nosyl 20 without significant variation in yield of 
dihydropyridinone. The sterically bulky 2,4,6-
triisopropylbenzene sulfonyl substituent could also be installed, 
although the isolated yield of 21 was much reduced. Pleasingly, 
an alkyl substituted sulfonyl ketimine also proved reactive, 
generating methanesulfonyl derivative 22 in good yield without 
loss of stereoselectivity. 
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Table 2 Variation of the Sulfonyl Substituent 
 
Entry -SO2R yield (%)
a dr (anti:syn)b ee (anti, %)c 
1 
 
62 93:7 >99 
2 
 
59 90:10 99 
3 
 
66 >95:5 98 
4 
 
13 >95:5 93 
5 
 
59 92:8 99 
a Isolated yield; b Measured by 1H NMR; c Measured by chiral HPLC. 
Exploration of the Acetic Acid Nucleophile Scope 
The scope of the acetic acid component was initially examined 
using α,β-unsaturated benzenesulfonyl ketimine 6 (Scheme 6). 
Generally, the isolated yield of dihydropyridinone was higher 
when two equivalents of acetic acid was used rather than one 
(Method A c.f. Method B). Interestingly, product 
diastereoselectivity was marginally reduced in most cases when 
two equivalents of acetic acid was used. While the reason for 
this is not immediately clear, enantioselectivity remained 
excellent. Arylacetic acids containing para-, meta- and ortho-
tolyl substituents were all incorporated in high yields and 
excellent stereoselectivities (23-25), demonstrating that ortho-
substitution has no detrimental effect on the course of the 
reaction, unlike in our previous synthesis of 
dihydropyridinones9 amongst other examples.7,12a,12c para-
Phenyl as well as 1- and 2-naphthyl substitution gave the 
desired dihydropyridinones (26-28) in moderate yields, 
although stereoselectivities remained excellent. Electron-rich 
and halogenated aromatics could also be easily incorporated 
with excellent stereocontrol (29-33), with an improvement in 
isolated yield for the most electron-rich substituents (cf. 8). The 
relative and absolute configuration of 31 was determined by X-
ray diffraction, with all other products assigned by analogy.18 
Other substituents included the heteroaromatic 3-thiophenyl 
dihydropyridinone 34, which was formed without consequence 
as long as two equivalents of activated acetic acid were 
employed, and the 3-pentenoic acid derivative 35,12d further 
expanding the scope of accessible motifs with functional 
handles for further derivatisation. Finally, the ketimine 
backbone was modified to incorporate a para-methoxyphenyl 
group in place of the phenyl substituent, resulting in the 
formation of 36 and 37 in moderate yield and high 
stereoselectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal Name ARTICLE 
This journal is © The Royal Society of Chemistry 2013 J. Name., 2013, 00, 1-3 | 5  
 
Scheme 6 Variation of acetic acid and ketimine and molecular representation of X-ray structure 31. Reaction conditons, A: Acetic acid (2 eq.), t-BuCOCl (2 eq.), i-
Pr2NEt (2 eq.), CH2Cl2; then ketimine (1 eq.), 4 (20 mol%), i-Pr2NEt (1 eq.), CH2Cl2. B: Acetic acid (1 eq.), t-BuCOCl (1 eq.), i-Pr2NEt (1 eq.), CH2Cl2; then ketimine (1 eq.), 
4 (20 mol%), i-Pr2NEt (1 eq.), CH2Cl2. Isolated yields; dr measured by 
1
H NMR; ee measured by chiral HPLC. 
Mechanistic Rationale 
The proposed mechanism of the reaction is outlined in Scheme 
7. Firstly, N-acylation of (−)-tetramisole 4 with mixed 
anhydride 38, formed in situ from phenylacetic acid and 
pivaloyl chloride, generates acyl isothiouronium 39. 
Deprotonation forms the (Z)-isothiouronium enolate, which 
undergoes a Michael addition / lactamisation cascade to give 
dihydropyridinone 42 with concomitant regeneration of the 
catalyst. A plausible pre-transition state assembly (43) that 
explains the relative and absolute configuration is shown. A 
stabilising interaction between the enolate oxygen and the 
sulfur of the isothiouronium ion locks the conformation of this 
species,17 thereby preventing Re-face attack through the 
stereodirecting phenyl group on tetramisole. 
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Scheme 7 Mechanistic rationale 
Derivatisation of the Dihydropyridinone Core 
The potential for derivatisation of the dihydropyridinones was 
next examined, first considering the possibility of converting 
the dihydropyridinone into a pyridine derivative. 
Dehydrogenation and desulfonylation of 8 using Pd/C in the 
presence of sodium formate gave pyridone 44 (Scheme 8). 
Subsequent treatment of 44 with tosyl chloride gave 
tetrasubstituted pyridine 45 in excellent yield. This route is 
complementary to our previous work regarding isothiourea 
mediated pyridine formation, which generates 2,4,6-
trisubstituted pyridines (cf. 46 and 47)10-11 in contrast to the 
2,3,4,6-tetrasubstituted pyridine formed here. Additionally, this 
methodology retains the 2-tosylate as a potential functional 
handle for further derivatisation.10 
 
Scheme 8 Formation of tetrasubstituted pyridine 45. Reaction conditions: a) 
Pd/C, HCO2Na, DMF, 60 °C; b) NaH, TsCl, DMF. 
In contrast to Pd/C, selective desulfonylation without 
dehydrogenation was achieved using sodium naphthalenide, 
which gave unprotected dihydropyridinone 48 in modest yield 
without loss of stereoselectivity (Scheme 9a). Alternatively, 
bromination at the 5-position proceeded smoothly upon 
treatment with Br2 to give the fully substituted 
dihydropyridinone 49 in excellent yield (Scheme 9b). Ring-
opening of 8 proved challenging, for example catalytic DMAP 
in methanol returned only starting material. However, ring- 
opening of 8 was possible using magnesium in methanol, which 
gave a moderate yield of keto-diester 50 in high 
enantioselectivity, alongside 60% of pyridone 44 from 
competing dehydrogenation / desufonylation under these more 
forcing conditions (Scheme 9c). Reduction of 8 with LiAlH4 
followed by an acidic workup afforded a good yield of acyclic 
enamine-diol 51 as a single diastereoisomer without loss of 
enantiopurity (Scheme 9d). It is perhaps surprising that the N-
sulfonyl enamine is isolable under these conditions, but the 
good isolated yield indicates significant stability of this 
functionality.20 
 
Scheme 9 Derivatisations of the dihydropyridinone core. Reaction conditions: a) 
Na / naphthalene (4 eq.), −78 °C; b) Br2, i-Pr2NEt; c) Mg / MeOH; d) i) 2 M LiAlH4, 
THF; ii) 0.1 M HCl. 
While all attempts at homo- or heterogeneous hydrogenation of 
the C-5,6 double bond in 8 to form the 2-piperidone returned 
only starting material, epoxidation was successful with m-
CPBA.21  This resulted in the formation of a single 
diastereoisomer of epoxide 52, containing four contiguous 
stereocentres (Scheme 10). The relative and absolute 
stereochemistry of 52 was confirmed through X-ray 
crystallography.22 
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Scheme 10 Epoxidation of 8 and molecular representation of X-ray structure 52 
Conclusions 
In conclusion, the scope of the isothiourea catalysed Michael 
addition / lactamisation of aryl and alkenyl acetic acids with 
α,β-unsaturated ketimines has been expanded, thereby allowing 
the synthesis of a variety of dihydropyridinone products. 
Derivatisation of the dihydropyridinone core has also been 
further demonstrated, affording a range of valuable skeletons 
from a single starting material. Further work in our laboratory 
is directed towards new Lewis base-catalysed reactions and 
exploring derivatisations of the functional building blocks they 
provide. 
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Experimental 
General Information 
Anhydrous CH2Cl2 was obtained from an Mbraun SPS-800 
system. Pet. ether is defined as petroleum ether 40-60 °C. All 
other solvents and commercial reagents were used as supplied 
without further purification unless stated otherwise. 
Room temperature (rt) refers to 20-25 °C. Temperatures of 
0 °C and –78 °C were obtained using ice/water and 
CO2(s)/acetone baths, respectively. 
Analytical thin layer chromatography (TLC) was performed 
on pre-coated aluminium plates (Kieselgel 60 F254 silica). TLC 
visualisation was carried out with ultraviolet light (254 nm), 
followed by staining with a 1% aqueous KMnO4 solution and 
heating. Flash column chromatography was performed on 
Kieselgel 60 silica in the solvent system stated. 
Melting points were recorded on an Electrothermal 9100 
apparatus.   
Optical rotations were measured on a Perkin Elmer 
Precisely/Model-341 polarimeter operating at the sodium D line 
with a 100 mm path cell at 20 °C. 
HPLC analyses were obtained on a Shimadzu HPLC 
consisting of a DGU-20A5 degasser, LC-20AT liquid 
chromatograph, SIL-20AHT autosampler, CMB-20A 
communications bus module, SPD-M20A diode array detector 
and a CTO-20A column oven which allowed the temperature to 
be set from 25-40 °C. Separation was achieved using a 
Chiralcel OD-H column or Chiralpak AD-H, and IA,  columns. 
Authentic racemic samples of chiral products were synthesised 
using achiral DHPB 7 or racemic tetramisole·HCl 4.  
Infrared spectra (νmax) were recorded on a Shimadzu 
IRAffinity-1 Fourier transform IR spectrophotometer as thin 
films using Pike MIRacle ATR accessory. Analysis was carried 
out using Shimadzu IRsolution v1.50 and only characteristic 
peaks are reported. 
1H and 13C{1H} spectra were acquired on either a Bruker 
Avance 300 {δH (300 MHz), δC (75 MHz), δF (282 MHz)}, a 
Bruker Avance II 400 {δH (400 MHz), δC (101 MHz), δF (376 
MHz)} or a Bruker Ultrashield 500 {δH (500 MHz), δC (126 
MHz), δF (471 MHz)} spectrometer at ambient temperature in 
the deuterated solvent stated. Chemical shifts, δ, are quoted in 
parts per million (ppm) and are referenced to the residual 
solvent peak. Coupling constants, J, are quoted in Hertz (Hz) to 
the nearest 0.1 Hz. The following abbreviations are used: s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, 
broad. 
Mass spectrometry (m/z) data were acquired by electrospray 
ionisation (ESI), electron impact (EI), chemical ionisation (CI), 
atmospheric solids analysis probe (ASAP), atmospheric 
pressure chemical ionisation (APCI) or nanospray ionisation 
(NSI) at the EPSRC National Mass Spectrometry Service 
Centre, Swansea. 
General Procedure A: Synthesis of α,β-unsaturated γ-N-sulfonyl 
ketimines from ethyl 3-benzoylacrylate 
A flame-dried flask containing a stirrer bar was charged with 
the requisite sulfonamide (1 eq.), ethyl 3-benzoylacrylate (1 
eq.) and CH2Cl2 (ca. 0.2 M). The resulting solution was stirred 
and cooled to 0 °C before Et3N (2 eq.) was added followed by 
TiCl4 (1 eq.) dropwise. The reaction mixture was allowed to 
warm to rt, a reflux condenser fitted to the flask, and the 
reaction heated at reflux overnight. The solvent was removed in 
vacuo, the titanium salts precipitated with Et2O and the 
suspension filtered. The filtrate was concentrated in vacuo, the 
residue cooled in an ice bath, and triturated with a small amount 
of Et2O (ca. 5 mL / g) with stirring. The resultant solid was 
collected by filtration and washed with further portions of cold 
Et2O. The solid was dried in vacuo to leave the pure ketimines. 
General Procedure B: Synthesis of Dihydropyridinones 
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A flask containing a stirrer bar was charged with CH2Cl2 (to 
give 0.4 M acid] , aryl acetic acid (2 eq.), i-Pr2NEt (2 eq.) and 
cooled to 0 °C. Pivaloyl chloride (2 eq.) was added and the 
reaction stirred for 30 minutes. (−)-Tetramisole·HCl 4 (20 
mol%) was added followed by the ketimine (1 eq.) and 
additional i-Pr2NEt (1 eq.) in CH2Cl2 (to give 0.4 M of 
ketimine). The reaction was allowed to warm to rt and stirred 
until complete by TLC. The reaction was quenched with 0.1 M 
HCl (~20 mL / mmol acid), the layers separated and the 
aqueous layer extracted with CH2Cl2 (2 × eq. vol.). The 
combined organics were dried over MgSO4, the solvent 
removed in vacuo on a rotary evaporator (<30 °C bath temp.), 
and the residue purified by flash chromatography in the solvent 
system stated. 
Preparation of Ketimines 
(2E,4E)-Ethyl 4-phenyl-4-((phenylsulfonyl)imino)but-2-
enoate 613a 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate 13 (1.84 mL, 10 mmol), benzenesulfonamide (1.57 
g, 10.0 mmol), NEt3 (2.8 mL, 20 mmol) and TiCl4 (1.1 mL, 10 
mmol) in CH2Cl2 (60 mL) gave the title compound after trituration 
as white crystals (2.04 g, 6.0 mmol, 60%); mp 51-52 °C {Lit.13a 51-
53 °C}; 1H NMR (500 MHz, CDCl3) δH: 1.35 (3H, t, J 7.0, 
OCH2CH3), 4.30 (2H, q, J 6.3, OCH2CH3), 6.24 (1H, d, J 16.2, 
C(2)H), 7.44 (2H, t, J 7.7, PhH), 7.51-7.56 (3H, m, PhH), 7.62 (1H, 
t, J 7.4, PhH), 8.03 (2H, s, PhH), 8.24 (1H, d, J 16.1, C(3)H). Data 
consistent with literature.13a 
(2E,3E)-Ethyl 4-phenyl-2-(tosylimino)but-3-enoate 923 
The starting ketone, (E)-ethyl 2-oxo-4-phenylbut-3-enoate, was 
prepared according the procedure outlined by Smith et al.5a 
Following general procedure A, the reaction of the above ketone (2.0 
g, 9.8 mmol), p-toluenesulfonamide (1.68 g, 9.8 mmol), NEt3 (2.8 
mL, 19.6 mmol) and TiCl4 (1.1 mL, 9.8 mmol) in CH2Cl2 (60 mL) 
gave 9 after purification by flash chromatography (EtOAc / pet. 
ether, 1:5) as a brown oil (1.51 g, 4.2 mmol, 43%); 1H NMR (300 
MHz, CDCl3) δH: 1.48 (3H, t, J 7.1, OCH2CH3), 2.43 (3H, s, 
NTsCH3), 4.55 (2H, q, J 7.1, OCH2CH3), 6.82 (1H, d, J 16.5, 
C(2)H), 7.29-7.56 (8H, m, ArH and C(3)H), 7.90 (2H, d, J 8.3, 
ArH). Data consistent with literature.23 
(2E,4E)-Ethyl 4-phenyl-4-(tosylimino)but-2-enoate 14a 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate (1.84 mL, 10 mmol), p-toluenesulfonamide (1.68 g, 
10.0 mmol), NEt3 (2.8 mL, 20 mmol) and TiCl4 (1.1 mL, 10 mmol) 
in CH2Cl2 (60 mL) gave the title compound after trituration (1.22 g, 
3.4 mmol, 34%) as white crystals; mp 53-54 °C; νmax (ATR): 2938, 
1714, 1545, 1304, 1157, 1094; 1H NMR (500 MHz, CDCl3) δH: 1.35 
(3H, t, J 6.8, OCH2CH3), 2.44 (3H, s, NTsCH3), 4.30 (2H, q, J 6.6, 
OCH2CH3), 6.22 (1H, d, J 16.2, C(2)H), 7.34 (2H, d, J 7.9, ArH), 
7.43 (2H, t, J 7.6, ArH), 7.56 (1H, t, J 7.4, ArH), 7.72 (2H, s, ArH), 
7.84-7.96 (2H, br s, ArH), 8.24 (1H, d, J 16.1, C(3)H); 13C{1H} 
NMR (101 MHz, CDCl3) δC: 14.1, 21.5, 61.5, 127.4, 128.5, 129.5, 
130.1, 132.8, 133.3, 135.7, 136.7, 137.6, 144.0, 164.5, 174.5; HRMS 
(ESI+): C19H20NO4S [M+H]
+ found 358.1107, requires 358.1108 
(−0.2 ppm).  
(2E,4E)-Ethyl 4-(((4-methoxyphenyl)sulfonyl)imino)-4-
phenylbut-2-enoate 14b 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate (0.92 mL, 5.0 mmol), 4-
methoxybenzenesulfonamide (0.94 g, 5.0 mmol), NEt3 (1.39 mL, 
10.0 mmol) and TiCl4 (0.55 mL, 5.0 mmol) in CH2Cl2 (30 mL), gave 
the title compound after trituration (0.95 g, 2.5 mmol, 50%) as an 
orange solid; mp 76-78 °C; νmax (ATR): 2985, 1716, 1552, 1494, 
1311, 1255, 1184, 1143, 1089, 1002, 975; 1H NMR (500 MHz, 
CDCl3) δH: 1.35 (1H, t, J 6.4, OCH2CH3), 3.38 (3H, s, ArOCH3), 
4.18-4.40 (2H, m, OCH2CH3), 6.21 (1H, d, J 16.2, C(2)H), 7.00 (2H, 
d, J 8.3, PhH), 7.43 (2H, t, J 7.5, PhH), 7.56 (1H, t, J 7.2, PhH), 
7.63-7.80 (2H, m, NSO2ArC(3)H), 7.97 (2H, d, J 3.7, 
NSO2ArC(2)H), 8.25 (1H, d, J 16.2, C(3)H); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 14.3, 55.8, 61.7, 114.2, 128.7, 129.7, 130.3, 132.3, 
132.9, 133.4, 136.0, 136.9, 160.8, 163.4, 170.3; HRMS (ESI+): 
C19H20NO5S [M+H]
+ found 374.1054, requires 374.1057 (−0.7 
ppm). 
(2E,4E)-Ethyl 4-(((4-nitrophenyl)sulfonyl)imino)-4-phenylbut-2-
enoate 14c 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate (0.92 mL, 5.0 mmol), 4-nitrobenzenesulfonamide 
(1.01 g, 5.0 mmol), NEt3 (1.39 mL, 10.0 mmol) and TiCl4 (0.55 mL, 
5.0 mmol) in CH2Cl2 (30 mL), gave the title compound after 
trituration as a yellow solid (1.32 g, 3.4 mmol, 68%); mp 84-86 °C; 
νmax (ATR): 3115, 2978, 1724, 1519, 1294, 1271, 1184, 1161, 1147, 
1091, 1029, 983; 1H NMR (400 MHz, CDCl3) δH: 1.35 (1H, t, J 7.1, 
OCH2CH3), 4.18 (2H, q, J 7.1, OCH2CH3), 6.32 (1H, d, J 16.1, 
C(2)H), 7.47 (2H, d, J 7.8, PhH), 7.61 (1H, t, J 7.5, PhH), 7.65-7.80 
(2H, m, PhH), 8.20-8.27 (3H, m, NSO2ArC(2)H and C(3)H), 8.39 
(2H, d, J 8.8, NSO2ArC(3)H);
 13C{1H} NMR (101 MHz, CDCl3) δC: 
14.3, 61.9, 124.4, 128.8, 129.0, 130.4, 134.0, 134.1, 135.3, 146.4, 
150.4, 164.5, 176.6; HRMS (ESI+): C18H17N2O6S [M+H]
+ found 
389.0802, requires 389.0802 (±0.0 ppm). 
(2E,4E)-Ethyl 4-phenyl-4-(((2,4,6-
triisopropylphenyl)sulfonyl)imino)but-2-enoate 14d 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate (7.3 mL, 40.0 mmol), 2,4,6-
triisopropylbenzenesulfonamide (11.34 g, 40.0 mmol), NEt3 (11.2 
mL, 80.0 mmol) and TiCl4 (4.4 mL, 5.0 mmol) in CH2Cl2 (120 mL), 
gave the title compound after trituration as a white solid (14.50 g, 
30.8 mmol, 77%); mp 104-106 °C; νmax (ATR): 2964, 1720, 1622, 
1150, 939; 1H NMR (500 MHz, CDCl3) δH: 1.25 (18H, app t, J 6.9, 
Ar(CH(CH3)2)3), 1.31 (3H, t, J 7.1, OCH2CH3), 2.90 (1H, septet, J 
6.8, ArC(4)CH(CH3)2), 4.20-4.29 (4H, m, OCH2CH3 and 
ArC(2)CH(CH3)2), 6.09 (1H, d, J 16.3, C(2)H), 7.16 (2H, s, 
NSO2ArC(3)H), 7.42 (2H, t, J 7.1, PhH), 7.49-7.61 (1H, m, PhH), 
7.76 (2H, d, J 6.1, PhH), 8.05 (1H, d, J 16.3, C(3)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 14.3, 23.8, 24.8, 30.2, 34.4, 61.6, 123.7, 
128.8, 130.3, 132.4, 133.3, 134.2, 136.2, 136.7, 150.0, 153.3, 164.6, 
173.8; HRMS (ESI+): C35H41N1O5Na1S1 ([M+Na]
+), found 
610.2603 requires 610.2592 (−1.2 ppm). 
(2E,4E)-Ethyl 4-((methylsulfonyl)imino)-4-phenylbut-2-enoate 
14e 
Following general procedure A, the reaction of ethyl 3-
benzoylacrylate (0.92 mL, 5.0 mmol), methanesulfonamide (0.48 g, 
5.0 mmol), NEt3 (1.39 mL, 10.0 mmol) and TiCl4 (0.55 mL, 5.0 
mmol) in CH2Cl2 (30 mL), gave the title compound after trituration 
as an orange solid (0.87 g, 3.1 mmol, 62%); mp 76-78 °C; νmax 
(ATR): 2991, 1718, 1639, 1579, 1554, 1442, 1365, 1309, 1292, 
1269, 1184, 1134, 1026, 970; 1H NMR (500 MHz, CDCl3) δH: 1.32 
(3H, t, J 7.1, OCH2CH3), 3.26 (3H, s, SO2CH3), 4.28 (2H, q, J 7.1, 
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OCH2CH3), 6.25 (1H, d, J 16.2, C(2)H), 7.47 (2H, t, J 7.8, PhH), 
7.60 (1H, t, J 7.1, PhH), 7.76 (2H, d, J 7.2, PhH), 8.13 (1H, d, J 
16.2, C(3)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 14.1, 43.0, 61.6, 
128.8, 130.1, 133.3, 133.5, 135.7, 136.2, 164.5, 175.3; HRMS 
(ESI+): C13H16NO4S [M+H]
+, found 282.0792, requires 282.0795 
(−0.9 ppm). 
(2E,4E)-Ethyl 4-(4-methoxyphenyl)-4-(tosylimino)but-2-enoate 
1713a 
A flame-dried flask containing a stirrer bar was charged with (+)-
diethyl (L)-tartrate 15 (0.66 mL, 3.0 mmol, 1 eq.) and anhydrous 
Et2O (6 mL). Periodic acid (0.68 g, 3.0 mmol, 1 eq.) was added and 
the reaction stirred for 3 h at rt. The suspension was filtered through 
cotton wool into a second flask, washing with anhydrous THF (7.5 
mL). The filtrate was treated with MgSO4 (1.0 g) and the resulting 
suspension cooled to 0 °C. 1-(4-Methoxyphenyl)-2-
(triphenylphosphoranylidene)ethanone 16 (1.85 g, 4.5 mmol, 1.5 eq.) 
was then added in one portion. The reaction was allowed to warm 
slowly to rt and stirred overnight. The solution was filtered and the 
solvent was removed in vacuo before purification of the crude 
material by flash chromatography on silica gel (Et2O / hexane 0:100 
to 30:70) to give (E)-ethyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate 
17 (0.92 g, 3.9 mmol, 87%) as a yellow solid. 
Following general procedure A with a modified work up, the 
reaction of (E)-ethyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate (0.77 
g, 3.3 mmol), p-toluenesulfonamide (0.57 g, 3.3 mmol), NEt3 (0.92 
mL, 6.6 mmol) and TiCl4 (0.36 mL, 3.3 mmol) in CH2Cl2 (17 mL) 
was followed by aqueous work up. The reaction mixture was 
quenched with water (30 mL) and extracted with EtOAc (×3), dried 
over MgSO4, filtered, and concentrated in vacuo. The crude residue 
was purified by Biotage® IsoleraTM 4 [SNAP Ultra 25 g, 75 mLmin-
1, hexane:EtOAc (75:25 2CV, 57:43 7CV)] to give the title 
compound 17 (1.08 g, 2.8 mmol, 85%) as a thick yellow oil; 1H 
NMR (500 MHz, CDCl3) δH: 1.34 (3H, t, J 6.7, OCH2CH3), 2.43 
(3H, s, NTsCH3), 3.85 (3H, s, ArOCH3), 4.29 (2H, q, J 6.9, 
OCH2CH3), 6.18 (1H, d, J 16.2, C(2)H), 6.90 (2H, d, J 8.2, 
NSO2ArH), 7.32 (2H, d, J 7.5, C(4)ArH), 7.75 (2H, d, J 7.0, 
NSO2ArH), 7.89 (2H, d, J 7.4, C(4)ArH), 8.01-8.21 (1H, m, C(3)H). 
Data consistent with literature.13a 
Preparation of Dihydropyridinones 
(3S,4S)-Ethyl 2-oxo-3,6-diphenyl-1-(phenylsulfonyl)-1,2,3,4-
tetrahydropyridine-4-carboxylate 8 
Following general procedure B, the reaction of phenylacetic acid 
(1.36 g, 10.0 mmol), i-Pr2NEt (1.73 mL, 10.0 mmol) and pivaloyl 
chloride (1.23 mL, 10.0 mmol) in CH2Cl2 (25 mL), followed by (−)-
tetramisole·HCl 4 (0.24 g, 1.0 mmol, 20 mol%), ketimine 6 (1.72 g, 
5.0 mmol), i-Pr2NEt (0.87 mL, 5.0 mmol) and CH2Cl2 (50 mL), for 1 
h gave a crude residue of 92 : 8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 8 (1.48 g, 3.2 mmol, 
64%, 92:8 dr) as a white solid; mp 128-129 °C; νmax (ATR): 2970, 
1722, 1448, 1155, 989; 
20
D
][α  +32.9 (c 0.55, CHCl3); HPLC 
(Chiralpak IA, 20% IPA / hexane, 0.5 mL/min, 254 nm, 30 °C): tR 
(3S, 4S): 13.2 min, tR (3R, 4R): 33.1 min, 98% ee; 
1H NMR (500 
MHz, CDCl3) δH: 1.04 (3H, t, J 7.1, OCH2CH3), 3.75 (1H, dd, J 9.6, 
4.8, C(4)H), 4.02 (2H, qd, J 7.5, 3.4, OCH2CH3), 4.10 (1H, d, J 9.6, 
C(3)H), 5.87 (1H, d, J 4.8, C(5)H), 7.01 (2H, dd, J 6.4, 2.4, 
C(3)PhH), 7.26-7.27 (3H, m, C(3)PhH), 7.38-7.40 (5H, m, 
C(6)PhH), 7.50 (2H, t, J 7.9, NSO2PhH), 7.65 (1H, t, J 7.4, 
NSO2PhH), 7.95 (2H, d, J 8.0, NSO2PhH); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 13.9, 45.1, 54.0, 61.6, 115.9, 126.1, 128.5, 128.6, 
128.7, 128.9, 129.5, 129.6, 132.3, 134.1, 136.7, 137.9, 139.2, 141.3, 
170.9, 172.2; HRMS (ESI+): C26H24NO5S [M+H]
+ found 462.1373, 
requires 462.1370 (+0.7 ppm). 
Ethyl 6-oxo-4,5-diphenyl-1-tosyl-1,4,5,6-tetrahydropyridine-2-
carboxylate 10 
Following general procedure B, the reaction of phenylacetic acid 
(54.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by DHPB 
7 (7.6 mg, 0.04 mmol, 20 mol%), ketimine 9 (71.6 mg, 0.2 mmol), i-
Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), for 1 h gave a crude 
residue of 59:41 dr. Purification by flash chromatography (Et2O / 
petrol, 1:4) gave 10 (37.9 mg, 0.08 mmol, 40%, 54:46 dr) as a white 
solid; mp 118-120 °C; νmax (ATR): 2987, 1724, 1597, 1363, 1170, 
1085, 1028; 1H NMR (300 MHz, CDCl3, both diastereoisomers) δH: 
1.37-1.43 (3H, m, OCH2CH3), 2.44 (3H, s, NTsCH3), 3.85 (1H, d, J 
10.2, CH), 4.03 (1H, d, J 5.8, CH), 4.08 (2H, q, J 5.3, 4.5, 
OCH2CH3), 4.28-4.52 (3H, m, OCH2CH3 and CH), 6.54-6.63 (1H, 
m, ArH), 6.65 (1H, d, J 4.2, ArH), 6.69 (1H, d, J 6.0, ArH), 6.85  
(1H, dd J 7.9, 1.5, ArH), 6.87-6.94 (1H, m, ArH), 7.00 (1H, dd, J 
7.4, 5.8, ArH), 7.04-7.13 (2H, m, ArH), 7.12-7.25 (7H, m, ArH), 
7.32 (2H, t, J 8.2, ArH), 8.11 (2H, d, J 8.4, ArH), 8.14-8.23 (2H, m, 
ArH); 13C{1H} NMR (101 MHz, CD2Cl2) δC: 13.9, 21.5, 44.1, 44.5, 
55.9, 57.2, 62.2, 126.9, 127.5, 127.6, 127.7, 127.8, 127.9, 127.9, 
128.5, 128.5, 128.8, 128.8, 128.9, 129.3, 129.3, 129.4, 129.5 129.6, 
129.9, 131.9, 132.8, 133.2, 135.4, 135.7, 138.8, 145.8, 170.2, 170.9; 
HRMS (ESI+): C27H26NO5S [M+H]
+ found 476.1527, requires 
476.1526 (+0.2 ppm). 
 (3S,4S)-Ethyl 2-oxo-3,6-diphenyl-1-tosyl-1,2,3,4-
tetrahydropyridine-4-carboxylate 18 
Following general procedure B, the reaction of phenylacetic acid 
(1.36 g, 10.0 mmol), i-Pr2NEt (1.73 mL, 10.0 mmol) and pivaloyl 
chloride (1.23 mL, 10.0 mmol) in CH2Cl2 (25 mL), followed by (−)-
tetramisole·HCl 4 (0.24 g, 1.0 mmol, 20 mol%), ketimine 14a (1.79 
g, 5.0 mmol), i-Pr2NEt (0.87 mL, 5.0 mmol) and CH2Cl2 (50 mL), 
for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 18 (1.47 g, 3.1 mmol, 
62%, 93:7 dr) as a white solid. Further recrystallisation (Et2O) gave 
18 as a single diastereoisomer (0.80 g, 1.68 mmol, 33%) as a white 
solid; mp 129-130 °C; νmax (ATR): 2978, 1726, 1363, 1166, 927; 
20
D
][α  +50.2 (c 0.49, CHCl3); HPLC (Chiralpak IA, 30% IPA / 
hexane, 0.5 mL/min, 254 nm, 30 °C): tR (3S, 4S): 20.0 min, tR (3R, 
4R): 40.6 min, >99% ee; 1H NMR (500 MHz, CDCl3) δH: 1.08 (3H, 
t, J 7.1, OCH2CH3), 2.49 (3H, s, TsCH3), 3.79 (1H, dd, J 9.6, 4.8, 
C(4)H), 4.05 (2H, qd, J 7.0, 3.7, OCH2CH3), 4.13 (1H, d, J 9.6, 
C(3)H), 5.89 (1H, d, J 4.8, C(5)H), 7.06 (2H, dd, J 6.9, 2.2, 
C(3)PhH), 7.30-7.33 (8H, m, PhH), 7.40-7.45 (2H, d, J 9.0, NTsH), 
7.87 (2H, d, J 9.0, NTsH); 13C{1H} NMR (101 MHz, CDCl3) δC: 
14.0, 21.9, 45.3, 54.1, 61.7, 115.8, 126.2, 128.1, 128.6, 128.7, 128.8, 
128.9, 129.3, 129.6, 135.5, 136.4, 136.8, 141.4, 145.3, 170.9, 172.0; 
HRMS (ESI+): C29H26NO5S [M+H]
+ found 476.1526, requires 
476.1526 (±0.0 ppm). 
(3S,4S)-Ethyl 1-((4-methoxyphenyl)sulfonyl)-2-oxo-3,6-diphenyl-
1,2,3,4-tetrahydropyridine-4-carboxylate 19 
Following general procedure B, the reaction of phenylacetic acid 
(54.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 14b 
(68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 
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mL), for 1 h gave a crude residue of 95:5 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 19 (58.2 mg, 0.12 
mmol, 59%, 90:10 dr) as a white solid; mp 114-115 °C; νmax (ATR): 
2976, 1720, 1593, 1531, 1496, 1446, 1365, 1303, 1261, 1161, 1087, 
1024, 979; 
20
D
][α  +18.1 (c 0.52, CHCl3); HPLC (Chiralpak AD-H, 
30% IPA / hexane, 1.0 mL/min, 254 nm, 30 °C): tR (3S, 4S): 17.5 
min, tR (3R, 4R): 55.6 min, 99% ee; 
1H NMR (400 MHz, CDCl3) δH: 
1.04 (3H, t, J 7.1, OCH2CH3), 3.74 (1H, dd, J 9.7, 4.8, C(4)H), 3.89 
(3H, s, ArOCH3), 4.01 (2H, qd, J 7.1, 1.7, OCH2CH3), 4.08 (1H, d, J 
9.7, C(3)H), 5.83 (1H, d, J 4.8, C(5)H), 6.93 (2H, d, J 9.1, 
NSO2ArH), 7.01-7.07 (2H, m, C(3)PhH), 7.26-7.30 (3H, m, 
C(3)PhH), 7.34-7.42 (5H, m, C(6)PhH), 7.87 (2H, d, J 9.1, 
NSO2ArH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 14.0, 45.2, 54.1, 
55.9, 61.7, 113.7, 115.7, 126.1, 128.1, 128.5, 128.7, 128.9, 129.8, 
130.5, 131.9, 135.5, 136.8, 141.3, 164.1, 170.9, 172.0; HRMS 
(ESI+): C27H26NO6S [M+H]
+ found 492.1470, requires 492.1475 
(−1.1 ppm). 
(3S,4S)-Ethyl 1-((4-nitrophenyl)sulfonyl)-2-oxo-3,6-diphenyl-
1,2,3,4-tetrahydropyridine-4-carboxylate 20 
Following general procedure B, the reaction of phenylacetic acid 
(54.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 14c 
(68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 
mL), for 1 h gave a crude residue of 95:5 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 20 (67 mg, 0.13 mmol, 
66%, >95:5 dr) as a white solid; mp 178-180 °C; νmax (ATR): 3066, 
1728, 1521, 1373, 1348, 1261, 1172, 1147, 1107, 1083, 1026, 931; 
20
D
][α  +4.5 (c 0.65, CHCl3); HPLC (Chiralpak IA, 30% IPA / 
hexane, 1.0 mL/min, 254 nm, 30 °C): tR (3S, 4S): 14.8 min, tR (3R, 
4R): 25.4 min, 98% ee; 1H NMR (500 MHz, CDCl3) δH: 1.12 (3H, t, 
J 7.1, OCH2CH3), 3.79 (1H, dd, J 7.8, 5.6, C(4)H), 4.07 (2H, qd, J 
7.8, 2.8, OCH2CH3), 4.15 (1H, d, J 5.6, C(3)H), 5.84 (1H, d, J 5.6, 
C(5)H), 7.13 (1H, dd, J 7.5, 1.8, C(3)PhH), 7.28-7.44 (8H, m, PhH), 
8.10 (2H, d, J 9.0, NSO2ArH), 8.30 (2H, d, J 9.0, NSO2ArH); 
13C{1H} NMR (101 MHz, CDCl3) δC: 14.1, 44.9, 53.7, 62.0, 116.2, 
123.7, 126.3, 128.4, 128.4, 128.7, 129.1, 129.3, 131.0, 135.0, 136.2, 
141.1, 144.4, 150.8, 170.7, 172.0; HRMS (ESI+): C26H23N2O7S 
[M+H]+ found 507.1213, requires 507.1220 (−1.5 ppm). 
(3S,4S)-Ethyl 2-oxo-3,6-diphenyl-1-((2,4,6-
triisopropylphenyl)sulfonyl)-1,2,3,4-tetrahydropyridine-4-
carboxylate 21 
Following general procedure B, the reaction of phenylacetic acid 
(54.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 14d 
(93.9 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 
mL), for 1 h gave a crude residue of >95:5 dr. Recrystallisation (pet. 
ether) gave 21 (15.4 mg, 0.03 mmol, 13%, >95:5 dr) as a white 
solid; mp 215-216 °C; νmax (ATR): 2960, 1734, 1715, 1599, 1172, 
938; 
20
D
][α  +110 (c 0.15, CH2Cl2); HPLC (Chiralpak AD-H, 5% IPA 
/ hexane, 1.5 mL/min, 254 nm, 40 °C): tR (3S, 4S): 3.44 min, tR (3R, 
4R): 3.66 min, 93% ee; 1H NMR (500 MHz, CDCl3) δH: 0.96 (3H, t, 
J 7.1, OCH2CH3), 1.27 (6H, d, J 6.5, NSO2ArCH(CH3)2), 1.29-1.37 
(12H, m, NSO2ArCH(CH3)2), 2.96 (1H, septet, J 6.9, 
NSO2ArCH(CH3)2), 3.72 (1H, dd, J 12.9, 3.4, C(4)H), 3.95 (2H, q, J 
7.1, OCH2CH3), 4.04 (1H, d, J 12.9, C(3)H), 4.18 (2H, d, J 6.6, 
NSO2ArCH(CH3)2), 5.80 (1H, d, J 3.4, C(5)H), 6.71-6.84 (2H, m, 
PhH), 7.17-7.23 (5H, m, PhH and NSO2ArH), 7.39-7.47 (3H, m, 
PhH ), 7.61-7.63 (2H, m, PhH); 13C{1H} NMR (101 MHz, CDCl3) 
δC: 13.9, 23.7, 23.8, 25.0, 25.4, 29.9, 34.4, 45.9, 53.3, 61.5, 114.8, 
123.8, 126.2, 127.8, 128.4, 128.6, 129.0, 129.2, 133.7, 135.5, 137.1, 
142.1, 152.4, 154.2, 171.0, 171.2; HRMS (ESI+): C35H41NO5SNa 
[M+Na]+ found 610.2592, requires 610.2603 (−1.2 ppm). 
 (3S,4S)-Ethyl 1-(methylsulfonyl)-2-oxo-3,6-diphenyl-1,2,3,4-
tetrahydropyridine-4-carboxylate 22 
Following general procedure B, the reaction of phenylacetic acid 
(54.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 14e 
(68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 
mL), for 1 h gave a crude residue of 91:9 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 22 (47.1 mg, 0.12 
mmol, 59%, 92:8 dr) as a white solid; mp 131-132 °C; νmax (ATR): 
2916, 1708, 1653, 1496, 1446, 1344, 1165, 1151, 1118, 960; 
20
D
][α  
−6.3 (c 0.51, CHCl3); HPLC (Chiralpak IA, 30% IPA / hexane, 0.5 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 41.5 min, tR (3R, 4R): 45.0 
min, 99% ee; 1H NMR (500 MHz, CDCl3) δH: 1.18 (1H, t, J 7.1, 
OCH2CH3), 3.46 (3H, s, MsCH3), 3.78 (1H, t, J 6.3, C(4)H), 4.14 
(2H, q, J 7.1, OCH2CH3), 4.26 (1H, d, J 6.3, C(3)H), 5.76 (1H, d, J 
6.2, C(5)H), 7.20-7.48 (10H, m, PhH); 13C{1H} NMR (101 MHz, 
CDCl3) δC: 14.1, 43.9, 44.9, 53.2, 62.0, 114.3, 125.5, 128.2, 128.3, 
128.8, 129.9, 129.1, 135.0, 137.0, 141.2, 171.2, 173.0; HRMS 
(ESI+): C21H22NO5S [M+H]
+ found 400.1216, requires 400.1213 
(+0.7 ppm). 
(3S,4S)-Ethyl 2-oxo-6-phenyl-1-(phenylsulfonyl)-3-(p-tolyl)-
1,2,3,4-tetrahydropyridine-4-carboxylate 23 
Following general procedure B, the reaction of p-tolylacetic acid 
(60.1 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 23 (63.2 mg, 0.13 
mmol, 66%, 94:6 dr) as a white solid; mp 100-102 °C; νmax (ATR): 
2933, 1730, 1516, 1355, 1159, 929; 
20
D
][α  +31.1 (c 0.54, CH2Cl2); 
HPLC (Chiralpak IA, 20% IPA / hexane, 0.5 mL/min, 254 nm, 30 
°C): tR (3S, 4S): 30.4 min, tR (3R, 4R): 55.2 min, 98% ee; 
1H NMR 
(400 MHz, CDCl3) δH: 1.06 (3H, t, J 7.1, OCH2CH3), 2.29 (3H, s, p-
tolylArCH3), 3.72 (1H, dd, J 9.7, 4.8, C(4)H), 3.97-4.07 (3H, m, 
C(3)H and OCH2CH3), 5.84 (1H, d, J 4.8, C(5)H), 6.88 (2H, d, J 8.1, 
C(3)ArH), 7.07 (2H, d, J 7.9, C(3)ArH), 7.31-7.42 (5H, m, 
C(6)PhH), 7.49 (2H, t, J 7.4, NSO2PhH), 7.64 (1H, t, J 7.4, 
NSO2PhH), 7.94 (2H, d, J 1.5, NSO2PhH); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 14.2, 21.2, 45.2, 53.7, 61.7, 116.0, 126.2, 128.5, 
128.6, 128.7, 128.9, 129.5, 129.6, 132.3, 134.1, 136.7, 137.9, 139.2, 
141.3, 170.9, 172.2; HRMS (ESI+): C27H26NO5S [M+H]
+ found 
476.1524, requires 476.1526 (−0.5 ppm). 
(3S,4S)-Ethyl 2-oxo-6-phenyl-1-(phenylsulfonyl)-3-(m-tolyl)-
1,2,3,4-tetrahydropyridine-4-carboxylate 24 
Following general procedure B, the reaction of m-tolylacetic acid 
(60.1 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 24 (69.6 mg, 0.15 
mmol, 72%, 93:7 dr) as a white solid; mp 134-136 °C; νmax (ATR): 
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2922, 1726, 1516, 1359, 1155, 887; 
20
D
][α  +27.9 (c 0.64, CH2Cl2); 
HPLC (Chiralpak IA, 10% IPA / hexane, 1.0 mL/min, 254 nm, 30 
°C): tR (3S, 4S): 22.7 min, tR (3R, 4R): 62.7 min, 99% ee; 
1H NMR 
(500 MHz, CDCl3) δH: 1.05 (3H, t, J 7.1, OCH2CH3), 2.26 (3H, s, m-
tolylArCH3), 3.72 (1H, dd, J 9.5, 4.9, C(4)H), 3.98-4.07 (3H, m, 
C(3)H and OCH2CH3), 5.84 (1H, d, J 4.9, C(5)H), 6.77-6.81 (2H, m, 
C(3)ArH), 7.05 (1H, d, J 7.6, C(3)ArH), 7.14 (1H, t, J 7.6, 
C(3)ArH), 7.33-7.42 (5H, m, C(6)PhH), 7.50 (2H, t, J 7.9, 
NSO2PhH), 7.65 (1H, t, J 7.4, NSO2PhH), 7.96 (2H, d, J 1, 
NSO2PhH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 14.0, 21.5, 45.2, 
53.9, 61.7, 115.8, 125.6, 126.1, 128.6 (2 × C), 128.6, 128.7, 128.9, 
129.3, 129.5, 134.1, 135.3, 136.7, 138.4, 139.2, 141.3, 170.8, 172.0; 
HRMS (ESI+): C27H26NO5S [M+H]
+ found 476.1522, requires 
476.1526 (−0.9 ppm). 
(3S,4S)-Ethyl 2-oxo-6-phenyl-1-(phenylsulfonyl)-3-(o-tolyl)-
1,2,3,4-tetrahydropyridine-4-carboxylate 25 
Following general procedure B, the reaction of o-tolylacetic acid 
(60.1 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 25 (63.9 mg, 0.13 
mmol, 67%, 93:7 dr) as a white solid; mp 78-80 °C; νmax (ATR): 
2922, 1726, 1516, 1359, 1155, 887; 
20
D
][α  +45.8 (c 0.55, CH2Cl2); 
HPLC (Chiralpak IA, 10% IPA / hexane, 1.0 mL/min, 254 nm, 30 
°C): tR (3S, 4S): 16.3 min, tR (3R, 4R): 56.5 min, 99% ee; 
1H NMR 
(400 MHz, CDCl3) δH: 1.00 (1H, t, J 7.1, OCH2CH3), 2.25 (3H, s, o-
tolylArCH3), 3.85 (1H, dd, J 10.9, 4.3, C(4)H), 4.00 (2H, q, J 7.1, 
OCH2CH3), 4.31 (1H, d, J 10.9, C(3)H), 5.90 (1H, d, J 4.3, C(5)H), 
6.80 (1H, d, J 7.8, C(3)ArH), 7.09 (1H, td, J 7.8, C(3)ArH), 7.12-
7.20 (2H, m, C(3)ArH and C(3)ArH), 7.37-7.48 (5H, m, C(6)PhH), 
7.51 (2H, td, J 7.6, 1.7, NSO2PhH), 7.65-7.67 (1H, m, NSO2PhH), 
7.97 (2H, d, J 8.6, NSO2PhH); 
13C{1H} NMR (101 MHz, CDCl3) δC: 
13.9, 19.8, 44.4, 51.3, 61.7, 116.5, 126.2, 126.6, 128.2, 128.5, 128.6, 
128.7, 129.0, 129.5, 130.9, 133.0, 134.2, 136.6, 137.0, 139.2, 141.3, 
170.1, 172.2; HRMS (ESI+): C27H26NO5S [M+H]
+ found 476.1520, 
requires 476.1526 (−1.3 ppm). 
(3S,4S)-Ethyl 3-([1,1'-biphenyl]-4-yl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 26 
Following general procedure B, the reaction of 4-biphenylacetic acid 
(84.8 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 26 (82.2 mg, 0.15 
mmol, 76%, 92:8 dr) as a white solid; mp 72-74 °C; νmax (ATR): 
2978, 1730, 1489, 1448, 1369, 1170, 1112, 1087, 916; 
20
D
][α  +16.2 
(c 0.73, CH2Cl2); HPLC (Chiralpak IA, 10% IPA / hexane, 1.0 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 59.4 min, tR (3R, 4R): 77.6 
min, 97% ee; 1H NMR (400 MHz, CDCl3) δH: 1.06 (3H, t, J 7.1, 
OCH2CH3), 3.79 (1H, dd, J 9.9, 4.7, C(4)H), 4.03 (2H, q, J 7.1, 
OCH2CH3), 4.13 (1H, d, J 9.9, C(3)H), 5.89 (1H, d, J 4.7, C(5)H), 
7.08 (2H, d, J 8.2, C(3)ArH), 7.27-7.57 (14H, m, ArH and 
NSO2PhH), 7.54-7.66 (1H, m, C(3)p-PhH), 7.96 (2H, dd, J 8.5, 1.0, 
NSO2PhH); 
13C{1H} NMR (101 MHz, CDCl3) δC: 14.0, 45.3, 53.9, 
61.8, 116.1, 126.2, 127.2, 127.6 (2 × C), 128.6, 128.7, 128.9, 129.0, 
129.1, 129.5, 134.2, 134.4, 136.6, 139.2, 140.6, 141.1, 141.4, 170.9, 
172.1; HRMS (ESI+): C32H28NO5S [M+H]
+ found 538.1677, 
requires 538.1683 (−1.1 ppm). 
(3S,4S)-Ethyl 3-(naphthalen-2-yl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 27 
Following general procedure B, the reaction of 2-naphthaleneacetic 
acid (74.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 91:9 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 27 (63.7 mg, 0.12 
mmol, 62%, 92:8 dr) as a white solid; mp 178-180 °C; νmax (ATR): 
2978, 1774, 1446, 1359, 1166, 1124, 1097, 1012; 
20
D
][α  +17.3 (c 
0.55, CH2Cl2); HPLC (Chiralpak AD-H, 30% IPA / hexane, 1.0 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 18.6 min, tR (3R, 4R): 30.8 
min, 97% ee; 1H NMR (400 MHz, CDCl3) δH: 0.95 (1H, t, J 7.1, 
OCH2CH3), 3.86 (1H, dd, J 9.9, 4.7, C(4)H), 3.96 (2H, qd, J 10.8, 
7.1, OCH2CH3), 4.26 (1H, dd, J 9.9, C(3)H), 5.84 (1H, d, J 5.2, 
C(5)H), 7.05 (1H, dd, J 8.5, 1.9, C(3)ArH), 7.34-7.57 (10H, m, 
ArH), 7.62-7.83 (4H, m, ArH), 7.97 (2H, dd, J 6.8, 1.2, NSO2PhH); 
13C{1H} NMR (101 MHz, CDCl3) δC: 14.0, 45.2, 54.3, 61.7, 116.0, 
126.0, 126.2, 126.4, 127.8, 128.2, 128.6, 128.7, 128.7, 128.8, 129.0, 
129.6, 132.8, 133.0, 133.3, 134.2 (2 × C), 136.7, 139.2, 141.4, 170.8, 
172.0; HRMS (ESI+): C30H26NO5S [M+H]
+ found 512.1522, 
requires 512.1526 (−0.8 ppm). 
(3S,4S)-Ethyl 3-(naphthalen-1-yl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 28 
Following general procedure B, the reaction of 1-naphthaleneacetic 
acid (74.5 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 91:9 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave lactam 28 (70.8 mg, 
0.14 mmol, 69%, 92:8 dr) as a white solid; mp 176-178 °C; νmax 
(ATR): 2978, 1721, 1446, 1166, 931; 
20
D
][α  −14.7 (c 0.58, CH2Cl2); 
HPLC (Chiralpak IA, 10% IPA / hexane, 1.0 mL/min, 211 nm, 30 
°C): tR (3S, 4S): 30.7 min, tR (3R, 4R): 98.1 min, 97% ee; 
1H NMR 
(400 MHz, CDCl3) δH: 0.95 (1H, t, J 7.1, OCH2CH3), 3.89-4.06 (3H, 
m, C(4)H and OCH2CH3), 4.91 (1H, d, J 8.6, C(3)H), 5.84 (1H, d, J 
5.2, C(5)H), 7.12-7.20 (1H, m, C(3)ArH), 7.33-7.36 (1H, m, 
C(3)ArH), 7.39-7.50 (5H, m, C(6)PhH), 7.50-7.56 (2H, t, J 7.4, 
NSO2PhH), 7.66-7.72 (1H, m, NSO2PhH), 7.72-7.76 (1H, m, 
C(3)ArH),7.80 (1H, d, J 8.3, C(3)ArH), 7.87 (1H, dd, J 6.8, 2.7, 
C(3)ArH), 7.99 (2H, dd, J 6.8, 1.2, NSO2PhH); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 13.8, 44.6, 51.3, 61.7, 115.8, 123.2, 125.2, 125.9, 
126.2, 126.7, 126.8, 128.6, 128.6, 128.9, 129.1, 129.3, 129.6, 131.0, 
131.7, 134.2 (2 × C), 136.7, 139.0, 141.4, 170.9, 171.9; HRMS 
(ESI+): C30H26NO5S [M+H]
+ found 512.1523, requires 512.1526 
(−0.6 ppm). 
(3S,4S)-Ethyl 3-(3,4-dimethoxyphenyl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 29 
Following general procedure B, the reaction of 3,4-
dimethoxyphenylacetic acid (78.4 mg, 0.4 mmol), i-Pr2NEt (70 µL, 
0.4 mmol) and pivaloyl chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 
mL), followed by (−)-tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 
mol%), ketimine 6 (68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) 
and CH2Cl2 (2.0 mL), for 1 h gave a crude residue of 93:7 dr. 
Purification by flash chromatography (Et2O / pet. ether, 2:3) gave 29 
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(81.0 mg, 0.16 mmol, 78%, 97:3 dr) as a white solid; mp 126-128 
°C; νmax (ATR): 2937, 1782, 1593, 1516, 1448, 1367, 1298, 1224, 
1143, 1087, 1026, 979; 
20
D
][α  +32.6 (c 0.53, CH2Cl2); HPLC 
(Chiralpak IA, 30% IPA / hexane, 0.5 mL/min, 254 nm, 30 °C): tR 
(3S, 4S): 38.0 min, tR (3R, 4R): 53.5 min, 98% ee; 
1H NMR (500 
MHz, CDCl3) δH: 1.08 (3H, t, J 7.1, OCH2CH3), 3.72 (1H, dd, J 9.8, 
4.8, C(4)H), 3.75 (3H, s, C(3)ArOCH3), 3.83 (3H, s, C(3)ArOCH3), 
3.94-4.11 (3H, m, C(3)H and OCH2CH3), 5.86 (1H, d, J 4.7, C(5)H), 
6.50 (1H, d, J 1.9, C(3)ArH), 6.58 (1H, dd, J 8.2, 2.0, C(3)ArH), 
6.75 (1H, d, J 8.3, C(3)ArH), 7.35-7.40 (5H, m, C(6)PhH), 7.40 (2H, 
t, J 7.9, NSO2PhH), 7.64 (1H, t, J 7.5, NSO2PhH), 7.95 (2H, d, J 7.4, 
NSO2PhH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 14.1, 45.3, 53.7, 
56.0 (2 × C), 61.7, 111.2, 111.6, 116.0, 121.1, 126.1, 127.7, 128.6, 
128.7, 129.0, 129.5, 134.1, 136.7, 139.3, 141.3, 148.9, 149.0, 170.9, 
172.2; HRMS (ESI+): C28H31N2O7S [M+NH4]
+ found 539.1842, 
requires 539.1846 (−0.8 ppm). 
(3S,4S)-Ethyl 3-(4-(dimethylamino)phenyl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 30 
Following general procedure B, the reaction of 4-
(dimethylamino)phenylacetic acid (71.7 mg, 0.4 mmol), i-Pr2NEt 
(70 µL, 0.4 mmol) and pivaloyl chloride (50 µL, 0.4 mmol) in 
CH2Cl2 (1.0 mL), followed by (−)-tetramisole·HCl 4 (9.6 mg, 0.04 
mmol, 20 mol%), ketimine 6 (68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 
0.2 mmol) and CH2Cl2 (2.0 mL), for 1 h gave a crude residue of 92:8 
dr. Purification by flash chromatography (Et2O : pet. ether, 2:3) gave 
30 (80.3 mg, 0.16 mmol, 80%, 93:7 dr) as a white solid; mp 178-180 
°C; νmax (ATR): 2933, 1730, 1516, 1355, 1159, 929; 
20
D
][α  +30.6 (c 
0.51, CH2Cl2); HPLC (Chiralpak IA, 10% IPA / hexane, 1.0 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 30.4 min, tR (3R, 4R): 55.2 
min, 99% ee; 1H NMR (400 MHz, CDCl3) δH: 1.09 (3H, t, J 7.1, 
OCH2CH3), 2.90 (6H, s, N(CH3)2), 3.68 (1H, dd, J 9.4, 5.0, C(4)H), 
3.95-4.08 (3H, m, C(3)H and OCH2CH3), 5.85 (1H, d, J 5.0, C(5)H), 
6.59 (2H, d, J 8.8, C(3)ArH ), 6.85 (2H, d, J 8.7, C(3)ArH), 7.36-
7.40 (5H, m, C(6)PhH), 7.45-7.53 (2H, m, NSO2PhH), 7.64 (1H, tt, J 
7.1, 1.2, NSO2PhH), 7.94 (2H, dd, J 8.5, 1.2, NSO2PhH); 
13C{1H} 
NMR (126 MHz, CDCl3) δC: 14.1, 40.6, 45.4, 53.3, 61.6, 112.7, 
116.2, 122.7, 126.2, 128.6, 128.6, 128.8, 129.3, 129.5, 134.0, 136.9, 
139.4, 141.2, 150.3, 171.1, 172.5; HRMS (ESI+): C28H29N2O5S 
[M+H]+ found 505.1786, requires 505.1792 (−1.1 ppm). 
(3S,4S)-Ethyl 3-(4-methoxyphenyl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 31 
Following general procedure B, the reaction of 4-
methoxyphenylacetic acid (66.4 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 
mmol) and pivaloyl chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), 
followed by (−)-tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), 
ketimine 6 (68.7 mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and 
CH2Cl2 (2.0 mL), for 1 h gave a crude residue of 92:8 dr. 
Purification by flash chromatography (Et2O / pet. ether, 2:3) gave 31 
(75.5 mg, 0.15 mmol, 74%, 92:8 dr) as a white solid; mp 152-154 
°C; νmax (ATR): 2960, 1732, 1716, 1514, 1165, 920; 
20
D
][α  +28.9 (c 
0.54, CH2Cl2); HPLC (Chiralpak AD-H, 20% IPA / hexane, 1.0 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 25.5 min, tR (3R, 4R): 42.8 
min, 98% ee; 1H NMR (500 MHz, CDCl3) δH: 1.06 (3H, t, J 7.1, 
OCH2CH3), 3.71 (1H, dd, J 10.0, 4.6, C(4)H), 3.76 (3H, s, 
C(3)ArOCH3), 3.97-4.06 (3H, m, C(3)H and OCH2CH3), 5.86 (1H, 
d, J 4.6, C(5)H), 6.76-6.84 (2H, m, C(3)ArH ), 6.88-6.96 (2H, m, 
C(3)ArH), 7.31-7.43 (5H, m, C(6)PhH), 7.46-7.54 (2H, m, 
NSO2PhH), 7.65 (1H, m, NSO2PhH), 7.90-7.97(2H, m, NSO2PhH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 14.1, 45.4, 53.6, 53.5, 61.7, 
114.2, 116.2, 126.2, 127.3, 128.6, 128.6, 128.9, 129.5, 129.8, 134.1, 
136.7, 139.2, 141.2, 159.4, 171.0, 172.3; HRMS (ESI+): 
C27H26NO6S [M+H]
+ found 492.1473, requires 492.1475 (−0.5 
ppm). 
(3S,4S)-Ethyl 3-(4-chlorophenyl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 32 
Following general procedure B, the reaction of 4-chlorophenylacetic 
acid (68.2 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 2 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 32 (53.5 mg, 0.11 
mmol, 54%, 94:6 dr) as a white solid; mp 136-138 °C; νmax (ATR): 
2978, 1724, 1683, 1448, 1367, 1168, 1087, 921; 
20
D
][α  +33.3 (c 
0.55, CH2Cl2); HPLC (Chiralpak IA, 30% IPA / hexane, 0.5 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 26.6 min, tR (3R, 4R): 42.0 
min, 95% ee; 1H NMR (400 MHz, CDCl3) δH: 1.06 (1H, t, J 7.1, 
OCH2CH3), 3.72 (1H, dd, J 10.5, 4.2, C(4)H), 3.94-4.09 (3H, m, 
C(3)H and OCH2CH3), 5.86 (1H, d, J 4.5, C(5)H ), 6.93 (2H, d, J 
8.4, C(3)ArH), 7.25 (2H, d, J 8.5, C(3)ArH), 7.35-7.39 (5H, m, 
C(6)PhH), 7.46-7.54 (2H, m, NSO2PhH), 7.66 (1H, tt, J 7.1, 1.2, 
NSO2PhH), 7.93 (2H, dd, J 8.5, 1.2, NSO2PhH); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 14.0, 45.1, 53.6, 61.9, 116.0, 126.2, 128.7, 128.7, 
129.1, 129.1, 129.5, 130.2, 133.9, 134.2, 134.3, 136.4, 139.1, 141.4, 
170.7, 171.8; HRMS (ESI+): C26H23N
35ClO5S [M+H]
+ found 
496.0981, requires 496.0980 (+0.2 ppm). 
(3S,4S)-Ethyl 3-(4-bromophenyl)-2-oxo-6-phenyl-1-
(phenylsulfonyl)-1,2,3,4-tetrahydropyridine-4-carboxylate 33 
Following general procedure B, the reaction of 4-bromophenylacetic 
acid (86.0 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 2 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 33 (64.6 mg, 0.13 
mmol, 60%, 94:6 dr) as a white solid; mp 140-142 °C; νmax (ATR): 
2976, 1726, 1710, 1448, 1168, 925; 
20
D
][α  +31.1 (c 0.54, CH2Cl2); 
HPLC (Chiralpak IA, 30% IPA / hexane, 0.5 mL/min, 254 nm, 30 
°C): tR (3S, 4S): 30.4 min, tR (3R, 4R): 45.8 min, 95% ee; 
1H NMR 
(400 MHz, CDCl3) δH: 1.07 (1H, t, J 7.1, OCH2CH3), 3.72 (1H, dd, J 
10.5, 4.2, C(4)H), 3.94-4.09 (3H, m, C(3)H and OCH2CH3), 5.85 
(1H, d, J 4.5, C(5)H), 6.87 (2H, d, J 8.4, C(3)ArH), 7.32-7.44 (7H, 
m, C(3)ArH and C(6)PhH), 7.46-7.55 (2H, m, NSO2PhH), 7.66 (1H, 
tt, J 7.1, 1.2, NSO2PhH), 7.93 (2H, d, J 8.5, NSO2PhH); 
13C{1H} 
NMR (101 MHz, CDCl3) δC: 14.0, 45.1, 53.6, 61.9, 115.9, 122.3, 
126.2, 128.7, 128.7, 129.1, 129.5, 130.5, 132.0, 134.3, 134.4, 136.4, 
139.1, 141.4, 170.6, 171.7; HRMS (ESI+): C26H23N
79BrO5S [M+H]
+ 
found 540.0473, requires 540.0475 (−0.3 ppm). 
(3S,4S)-Ethyl 2-oxo-6-phenyl-1-(phenylsulfonyl)-3-(thiophen-3-
yl)-1,2,3,4-tetrahydropyridine-4-carboxylate 34 
Following general procedure B, the reaction of 3-thiophenylacetic 
acid (56.9 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 6 (68.7 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 1 h gave a crude residue of 85:15 dr. Purification by flash 
chromatography (Et2O / pet. ether, 1:4) gave 34 (59.7 mg, 0.13 
mmol, 64%, 92:8 dr) as a white solid; mp 112-114 °C; νmax (ATR): 
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2924, 1728, 1448, 1357, 1303, 1219, 1165, 1120, 1083, 1056, 1029, 
1001, 842; 
20
D
][α  +29.3 (c 0.59, CH2Cl2); HPLC (Chiralpak IA, 20% 
IPA / hexane, 0.5 mL/min, 254 nm, 30 °C): tR (3S, 4S): 40.3 min, tR 
(3R, 4R): 72.1 min, 97% ee; 1H NMR (400 MHz, CDCl3) δH: 1.14 
(3H, t, J 7.1, OCH2CH3), 3.68 (1H, dd, J 8.1, 5.5, C(4)H), 4.08 (2H, 
qd, J 7.4, 3.6, OCH2CH3), 4.24 (1H, dd, J 8.1, C(3)H), 5.85 (1H, d, J 
5.5, C(5)H), 6.77 (1H, dd, J 5.0, 1.3, C(3)ArH), 7.03 (1H, ddd, J 2.9, 
1.3, 0.6, C(3)ArH), 7.23-7.26 (1H, m, C(3)ArH), 7.34-7.37 (5H, m, 
C(6)PhH), 7.43-7.54 (2H, m, NSO2PhH), 7.64 (1H, tt, J 7.4, 1.2, 
NSO2PhH), 7.92 (2H, dd, J 8.5, 1.2, NSO2PhH); 
13C{1H} NMR (126 
MHz, CDCl3) δC: 14.1, 44.6, 49.2, 61.8, 115.3, 123.6, 126.1, 126.5, 
126.9, 128.6, 128.6, 128.9, 129.4, 134.1, 134.9, 136.6, 139.1, 141.4, 
170.7, 171.0; HRMS (ESI+): C24H22NO5S2 [M+H]
+ found 468.0933, 
requires 468.0934 (−0.2 ppm). 
(3R,4S)-Ethyl 2-oxo-6-phenyl-1-(phenylsulfonyl)-3-((E)-prop-1-
en-1-yl)-1,2,3,4-tetrahydropyridine-4-carboxylate 35 
Following general procedure B, the reaction of (E)-pent-3-enoic acid 
(82 µL, 0.8 mmol), i-Pr2NEt (140 µL, 0.8 mmol) and pivaloyl 
chloride (50 µL, 0.4 mmol) in CH2Cl2 (2.0 mL), followed by (−)-
tetramisole·HCl 4 (19.2 mg, 0.08 mmol, 20 mol%), ketimine 6 
(137.2 mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and CH2Cl2 (4.0 
mL), for 1 h gave a crude residue of 92:8 dr. Purification by flash 
chromatography (EtOAc / pet. ether, 1:9) gave 35 (89.5 mg, 0.21 
mmol, 53%, 88:12 dr) as a white solid; mp 56-58 °C; νmax (ATR): 
2976, 1732, 1448, 1367, 1170, 1085, 1026, 926; 
20
D
][α  +67.0 (c 
0.53, CH2Cl2); HPLC (Chiralpak OD-H, 5% IPA / hexane, 1.0 
mL/min, 2211 nm, 40 °C): tR (3S, 4R): 15.8 min, tR (3R, 4S): 19.5 
min, 98% ee; 1H NMR (400 MHz, CDCl3) δH: 1.25 (3H, t, J 7.1, 
OCH2CH3), 1.66 (3H, dd, J 6.3, 1.4, C(3)CHCHCH3), 3.37 (1H, dd, 
J 8.4, 5.4, C(4)H), 3.47 (1H, t, J 8.2, C(3)H), 4.15 (2H, qd, J 7.1, 
1.4, OCH2CH3), 5.30 (1H, ddq, J 15.1, 8.1, 1.5, C(3)CHCHCH3), 
5.64 (1H, m, C(3)CHCHCH3), 5.80 (1H, d, J 5.4, C(5)H), 7.30-7.38 
(5H, m, C(6)PhH), 7.44-7.51 (2H, m, NSO2PhH), 7.62 (1H, tt, J 7.0, 
1.2, NSO2PhH), 7.90 (2H, dt, J 8.6, 1.5, NSO2PhH); 
13C{1H} NMR 
(101 MHz, CDCl3) δC: 14.3, 18.2, 43.7, 51.5, 61.7, 115.7, 123.8, 
126.1, 128.5, 128.6, 128.8, 129.4, 132.1, 134.1, 136.9, 139.2, 141.2, 
170.9, 171.8; HRMS (ESI+): C23H24NO5S [M+H]
+ found 426.1368, 
requires 426.1370 (−0.4 ppm). 
 (3S,4S)-Ethyl 6-(4-methoxyphenyl)-2-oxo-3-phenyl-1-tosyl-
1,2,3,4-tetrahydropyridine-4-carboxylate 36 
Following general procedure B, the reaction of phenylacetic acid (55 
mg, 0.4 mmol), i-Pr2NEt (70 µL, 0.4 mmol) and pivaloyl chloride 
(49 µL, 0.4 mmol) in CH2Cl2 (1.0 mL), followed by (−)-
tetramisole·HCl 4 (9.6 mg, 0.04 mmol, 20 mol%), ketimine 17 (77 
mg, 0.2 mmol), i-Pr2NEt (35 µL, 0.2 mmol) and CH2Cl2 (2.0 mL), 
for 24 h gave a crude residue of 90:10 dr. Purification by flash 
chromatography (Et2O / pet. ether, 40:60) gave 36 (59 mg, 0.12 
mmol, 58%, 90:10 dr) as a white solid; mp 132-134 °C; νmax (ATR): 
2929, 1718, 1606, 1501, 1361, 1161, 926;
20
D
][α +32.5 (c 0.52, 
CH2Cl2); HPLC (Chiralpak IA, 30% IPA / hexane, 1.0 mL/min, 254 
nm, 30 °C): tR (3S, 4S): 14.1 min, tR (3R, 4R): 22.4 min, 99% ee; 
1H 
NMR (500 MHz, CD2Cl2) δH: 1.04 (3H, t, J 7.0, OCH2CH3), 2.47 
(3H, s, NSO2ArCH3), 3.67 (1H, dd, J 9.7, 4.9, C(4)H), 3.84 (3H, s, 
C(6)ArOCH3), 3.99 (2H, qd, J 7.2, 2.8, OCH2CH3), 4.05 (1H, d, J 
9.7, C(3)H), 5.78 (1H, d, J 4.8, C(5)H), 6.89-6.95 (4H, m, C(3)PhH 
and C(6)ArH), 7.22-7.28 (3H, m, C(3)PhH), 7.32-7.40 (4H, m, 
NSO2ArH and C(6)ArH), 7.77-7.82 (2H, m, NSO2ArH); 
13C{1H} 
NMR (125 MHz, CD2Cl2) δC: 14.2, 22.0, 45.4, 54.3, 55.9, 62.0, 
114.3, 114.7, 127.7 (×2), 128.4, 129.1, 129.7, 129.9, 130.1, 136.2, 
136.8, 141.4, 146.1, 160.6, 171.2, 172.4; HRMS (ESI+): 
C28H28NO6S [M+H]
+ found 506.1625, requires 506.1632 (−1.4 
ppm). 
 (3S,4S)-Ethyl 3-(4-(dimethylamino)phenyl)-6-(4-
methoxyphenyl)-2-oxo-1-tosyl-1,2,3,4-tetrahydropyridine-4-
carboxylate 37 
Following general procedure B, the reaction of 4-
(dimethylamino)phenylacetic acid (71.7 mg,  0.4 mmol), i-Pr2NEt 
(70 µL, 0.4 mmol) and pivaloyl chloride (50 µL, 0.4 mmol) in 
CH2Cl2 (1.0 mL), followed by (−)-tetramisole·HCl 4 (9.6 mg, 0.04 
mmol, 20 mol%), ketimine 17 (77.5 mg, 0.2 mmol), i-Pr2NEt (35 
µL, 0.2 mmol) and CH2Cl2 (2.0 mL), for 1 h gave a crude residue of 
95:5 dr. Purification by flash chromatography (Et2O / pet. ether, 1:4) 
gave 37 (52.0 mg, 0.095 mmol, 47%, 88:12 dr) as a white solid; mp 
144-146 °C; νmax (ATR): 2926, 1728, 1610, 1512, 1361, 1247, 1165, 
1087, 1027, 812; 
20
D
][α  +23.8 (c 0.55, CH2Cl2); HPLC (Chiralpak 
IA, 30% IPA / hexane, 1.0 mL/min, 254 nm, 30 °C): tR (3S, 4S): 16.7 
min, tR (3R, 4R): 19.9 min, 91% ee; 
1H NMR (500 MHz, CD2Cl2) 
δH: 1.09 (3H, t, J 7.1, OCH2CH3), 2.48 (3H, s, NSO2ArCH3), 2.90 
(6H, s, C(3)ArN(CH3)2), 3.61 (1H, dd, J 9.5, 5.0, C(4)H), 3.85 (3H, 
s, C(6)ArOCH3), 3.93 (1H, d, J 9.5, C(3)H), 4.02 (2H, qd, J 7.1, 3.9, 
OCH2CH3), 5.77 (1H, d, J 5.0, C(5)H), 6.58 (2H, d, J 8.8, C(3)ArH), 
6.76 (2H, d, J 8.7, C(3)ArH), 6.83-6.99 (2H, m, C(6)ArH), 7.26-7.44 
(4H, m, NSO2ArH and C(6)ArH), 7.80 (2H, d, J 8.4,  NSO2ArH); 
13C{1H} NMR (126 MHz, CD2Cl2) δC: 14.1, 21.8, 40.6, 45.4, 53.3, 
55.7, 61.7, 112.6, 114.1, 114.8, 123.1, 127.5, 129.5, 129.4, 129.5, 
129.6, 130.0, 136.8, 141.0, 145.8, 150.5, 160.4, 171.3, 172.8; HRMS 
(ESI+): C30H33N2O6S [M+H]
+ found 549.2047, requires 549.2054 
(−1.2 ppm). 
Derivatisations 
Ethyl 2-oxo-3,6-diphenyl-1,2-dihydropyridine-4-carboxylate 4424 
A solution of dihydropyridinone 8 (46.2 mg, 0.1 mmol, 1 eq.) and 
HCOONa (34.0 mg, 0.5 mmol, 5 eq.) in DMF (0.5 mL) was treated 
with 10% Pd/C (12 mol%) and stirred at 60 °C for 24 h. The reaction 
was allowed to cool to rt, diluted with water (5 mL), filtered through 
Celite®, and extracted with EtOAc (3 × 5 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo. The residue was purified by flash column chromatography 
(CH2Cl2 / MeOH, 19:1) to give 44 (27.6 mg, 0.086 mmol, 86%) as a 
white solid; mp 182-184 °C {Lit.24 214 °C (EtOAc)}; 1H NMR (500 
MHz, CDCl3) δH: 0.95 (3H, t, J 7.1, OCH2CH3), 4.07 (2H, q, J 7.1, 
OCH2CH3), 6.77 (1H, s, C(5)H), 7.37-7.41 (7H, m, PhH), 7.46 (2H, 
d, J 6.9, C(6)PhH), 7.78 (2H, d, J 7.7 C(6)PhH), 12.17 (1H, br s, 
NH); 13C{1H} NMR (126 MHz, CD2Cl2) δC: 13.7, 62.0, 104.7, 
126.7, 128.1, 128.2, 129.4, 129.6, 130.7, 132.4, 134.4, 143.5, 146.0, 
163.9, 165.7, 167.5. Data consistent with literature.24 
Ethyl 3,6-diphenyl-2-(tosyloxy)isonicotinate 45 
A stirred solution of pyridone 44 (31.9 mg, 0.1 mmol, 1 eq.) in 
anhydrous THF (1 mL) at −78 °C under an argon atmosphere was 
treated with NaH (60% wt., 6.0 mg, 0.15 mmol, 1.5 eq.) followed by 
a solution of tosyl chloride (28.6 mg, 0.15 mmol, 1.5 eq.) in 
anhydrous THF (0.5 mL). After 1 h, the reaction mixture was 
allowed to warm to rt, then heated to 60 °C for 3 h. The reaction was 
poured into ice water (10 mL), neutralised with K2CO3, and 
extracted with CHCl3 (3 × 10 mL). The combined organics were 
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dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
was purified by flash chromatography (Et2O / pet. ether, 3:7) to give 
pyridine 45 (44.6 mg, 0.094 mmol, 94%) as a white solid; mp 122-
134 °C; νmax (ATR): 2924, 1732, 1597, 1539, 1375, 1327, 1247, 
1192, 1178, 1168, 1155, 1024, 968; 1H NMR (500 MHz, CDCl3) δH: 
0.94 (3H, t, J 7.1, OCH2CH3), 2.47 (3H, s, OTsCH3), 4.07 (2H, q, J 
7.1, OCH2CH3), 7.29 (2H, d, J 8.1, OTsH), 7.31-7.35 (2H, m, PhH), 
7.37-7.49 (6H, m, PhH), 7.75-7.85 (4H, m, TsH and PhH), 7.99 (1H, 
s, C(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 13.6, 21.9, 62.0, 
118.1, 126.3, 127.1, 128.3, 128.4, 128.7, 128.7, 128.9, 129.6, 129.6, 
130.1, 133.3, 135.1, 136.6, 144.4, 144.9, 155.0, 155.3, 166.5; HRMS 
(ESI+): C27H24NO5S [M+H]
+ found 474.1364, requires 474.1370 
(−1.2 ppm). 
(3S,4S)-Ethyl 2-oxo-3,6-diphenyl-1,2,3,4-tetrahydropyridine-4-
carboxylate 48 
A solution of dihydropyridinone 8 (92.3 mg, 0.2 mmol, 1 eq.) in 
anhydrous THF (2 mL) at −78 °C under an argon atmosphere was 
treated dropwise with a pre-formed solution of sodium (18.4 mg, 0.8 
mmol, 4 eq.) and naphthalene (102.5 mg, 0.8 mmol, 4 eq.) in 
anhydrous THF (2 mL) that had been stirred for 1.5 h at rt. The 
reaction was monitored by TLC and when complete (1 h), quenched 
with brine (5 mL) and extracted with EtOAc (3 × 5 mL). The 
combined organics were dried over MgSO4, filtered, and the solvent 
removed in vacuo to obtain the crude product (>99:1 dr). 
Purification by flash chromatography (Et2O / pet. ether, 1:1) to give 
48 (29.5 mg, 0.092 mmol, 46%, >99:1 dr) as a white solid; mp 100-
102 °C; νmax (ATR): 3246, 2964, 1728, 1670, 1651, 1456, 1265, 
1155; 
20
D
][α  +136.5 (c 0.26, CH2Cl2); HPLC (Chiralpak OD-H, 30% 
IPA / hexane, 0.5 mL/min, 270 nm, 30 °C): tR (3S, 4S): 36.4 min, tR 
(3R, 4R): 29.2 min, 99% ee; 1H NMR (400 MHz, CDCl3) δH: 1.18 
(3H, J 7.1, OCH2CH3), 3.76 (1H, dd, J 7.5, 4.8, C(4)H), 4.13 (2H, q, 
J 7.1, OCH2CH3), 4.19 (1H, d, J 7.5, C(3)H), 5.43 (1H, dd, J 4.8, 
1.5, C(5)H), 7.29-7.35 (5H, m, C(3)PhH), 7.40-7.43 (2H, m, 
C(6)PhH), 7.45-7.47 (2H, m, C(6)PhH); 13C{1H} NMR (101 MHz, 
CDCl3) δC: 14.2, 46.7, 48.5, 61.5, 99.3, 125.3, 127.8, 128.4, 128.9, 
129.2, 129.6, 134.5, 137.3, 138.2, 170.8, 171.9; HRMS (ESI+): 
C20H20NO3 [M+H]
+ found 322.1443, requires 322.1438 (+1.6 ppm). 
(3S,4S)-Ethyl 5-bromo-2-oxo-3,6-diphenyl-1-(phenylsulfonyl)-
1,2,3,4-tetrahydropyridine-4-carboxylate 49 
A stirred solution of dihydropyridinone 8 (46.2 mg, 0.1 mmol, 1 eq.) 
in anhydrous CH2Cl2 (10 mL) at −78 °C under an argon atmosphere 
was treated dropwise with bromine (12.8 µL, 0.25 mmol, 2.5 eq.) 
dropwise. i-Pr2NEt (19.0 µL, 0.11 mmol, 1.1 eq.) was added and the 
reaction mixture allowed to warm to rt. The reaction was monitored 
by TLC and complete in 2 h. The reaction mixture was quenched 
with saturated aqueous Na2S2O3 (10 mL), the layers separated and 
the aqueous extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were washed with brine (10 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The crude product was purified 
by flash chromatography (Et2O / pet. ether, 1:4) to give 49 (46.3 mg, 
0.086 mmol, 86%, >99:1 dr) as a white solid; mp 130-132 °C; νmax 
(ATR): 2924, 1750, 1732, 1446, 1371, 1181, 1066, 885; 
20
D
][α  
−26.7 (c 0.61, CH2Cl2); HPLC (Chiralpak IA, 30% IPA / hexane, 1.0 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 10.9 min, tR (3R, 4R): 15.3 
min, 97% ee; 1H NMR (500 MHz, CDCl3) δH: 1.36 (3H, t, J 7.1, 
OCH2CH3), 4.00 (1H, d, J 3.4, C(4)H), 4.33 (2H, ddq, J 47.0, 10.8, 
7.1, OCH2CH3), 4.54 (1H, d, J 3.4, C(3)H), 7.19 (2H, d, J 7.5, 
C(3)PhH), 7.23-7.39 (10H, m, PhH), 7.55 (1H, t, J 7.4, NSO2PhH), 
7.59 (2H, t, J 7.4, NSO2PhH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 
14.2, 53.8, 54.4, 62.8, 110.2, 127.6, 127.9, 128.4, 128.6, 129.0, 
129.1, 129.3, 129.8, 133.9, 134.2, 134.9, 137.1, 139.0, 168.9, 170.4; 
HRMS (ESI+): C26H23N
79BrO5S [M+H]
+ found 540.0469, requires 
540.0475 (−1.1 ppm). 
(2S,3S)-1-Ethyl 4-methyl 2-(2-oxo-2-phenylethyl)-3-
phenylsuccinate 50 
A solution of dihydropyridinone 8 (46.2 mg, 0.1 mmol, 1 eq.) and 
magnesium turnings (24.3 mg, 1 mmol, 10 eq.) in MeOH (15 mL) 
was stirred at rt overnight. The reaction was quenched with 1 M HCl 
(15 mL) and extracted with CH2Cl2 (3 × 15 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash 
chromatography (Et2O / pet. ether, 1:9) to give 50 (12.4 mg, 0.035 
mmol, 35%, >99:1 dr) as a white solid; mp 80-82 °C; νmax (ATR): 
2916, 1718, 1681, 1448, 1398, 1336, 1271, 1251, 1153, 1002; 
20
D
][α  
+79.7 (c 0.47, CH2Cl2); HPLC (Chiralpak IA, 30% IPA / hexane, 0.5 
mL/min, 254 nm, 30 °C): tR (3S, 4S): 13.6 min, tR (3R, 4R): 16.7 
min, 97% ee; 1H NMR (500 MHz, CDCl3) δH: 0.88 (3H, t, J 7.1, 
OCH2CH3), 3.17 (1H, dd, J 17.3, 3.3, C(4)H
AHB), 3.58 (1H, dd, J 
17.3, 10.3, C(4) HAHB), 3.67-3.77 (4H, m, C(3)H and OCH3), 3.85 
(2H, m, OCH2CH3), 3.92 (1H, d, J 9.5, C(2)H), 7.26-7.34 (5H, m, 
PhH), 7.45 (2H, dd, J 8.3, 7.2, PhH), 7.52-7.59 (1H, m, PhH), 7.90-
7.97 (2H, m, PhH); 13C{1H} NMR (126 MHz, CDCl3) δC: 13.8, 38.4, 
44.8, 52.5, 53.5, 60.8, 128.0, 128.2, 128.7, 128.8 (2 × C), 133.4, 
135.8, 136.5, 172.6, 173.2, 197.7; HRMS (ESI+): C21H23O5 [M+H]
+ 
found 355.1542, requires 355.1540 (+0.6 ppm). Pyridone 44 (19.2 
mg, 0.06 mmol, 60%) was also isolated from this reaction. 
N-((3S,4S)-5-hydroxy-3-(hydroxymethyl)-1,4-diphenylpent-1-en-
1-yl)benzenesulfonamide 51 
A solution of dihydropyridinone 8 (46.2 mg, 0.1 mmol, 1 eq.) in 
anhydrous THF (1 mL) at 0 °C under an argon atmosphere was 
treated dropwise with 2.0 M LiAlH4 in THF (0.1 mL, 0.2 mmol, 2 
eq.). The reaction was stirred at 0 °C for 1 h and quenched with 0.1 
M HCl (5 mL). The reaction mixture was extracted with Et2O (3 × 5 
mL), the combined organic layers dried over MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash 
chromatography (Et2O / pet. ether, 1:19) to give 51 (27.6 mg, 0.065 
mmol, 65%, >99:1 dr) as a white solid; mp 74-76 °C; νmax (ATR): 
2953, 1887, 1490, 1448, 1330, 1170, 1112, 1039, 1010, 950; 
20
D
][α  
−1.1 (c 0.45, CH2Cl2); HPLC (Chiralpak AD-H, 30% IPA / hexane, 
1.0 mL/min, 254 nm, 30 °C): tR (3S, 4S): 9.2 min, tR (3R, 4R): 11.1 
min, 97% ee; 1H NMR (400 MHz, CDCl3) δH: 2.65 (1H, ddd, J 11.7, 
4.9, 3.1, C(4)H), 2.67-1.81 (1H, m, C(3)H), 3.18 (2H, d, J 5.2, 
C(3)CH2OH), 3.60 (1H, dd, J 11.5, 4.7, C(5)H
AHB), 3.65-3.73 (1H, 
m, C(5)HAHB), 5.59 (1H, dd, J 9.6, C(2)H), 7.09-7.19 (2H, m, 
C(4)PhH), 7.20-7.42 (6H, m, PhH), 7.41-7.50 (4H, m, PhH and 
NSO2PhH), 7.50-7.59 (1H, m, NSO2PhH), 7.75 (2H, dd, J 8.4, 1.3, 
NSO2PhH), 8.11 (1H, br s, NH); 
13C{1H} NMR (126 MHz, CDCl3) 
δC: 41.5, 48.6, 65.0, 65.8, 125.5, 127.4, 127.5, 127.5, 128.2, 128.3, 
128.6, 128.9, 129.0, 132.8, 137.5, 138.2, 140.3, 140.7; HRMS 
(ESI+): C24H25NO4SNa [M+Na]
+ found 446.1389, requires 446.1397 
(−1.7 ppm). 
(1S,4S,5R,6S)-Ethyl 3-oxo-1,4-diphenyl-2-(phenylsulfonyl)-7-
oxa-2-azabicyclo[4.1.0]heptane-5-carboxylate 52 
A solution of dihydropyridinone 8 (46.2 mg, 0.1 mmol, 1 eq.) in 
CH2Cl2 (1 mL) at 0 °C was treated with m-CPBA (70% wt., 37.0 
mg, 0.15 mmol, 1.5 eq.). The reaction was allowed to warm to rt and 
stirred for 24 h, before being quenched with sat. NaHCO3 (2 mL). 
The layers were separated and the aqueous layer extracted with 
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CH2Cl2 (3 × 5 mL). The combined organics were dried over MgSO4, 
filtered, and the solvent removed in vacuo to obtain the crude 
product (>99:1 dr). Purification by flash chromatography (Et2O / pet. 
ether, 1:4) gave 52 (34.2 mg, 0.072 mmol, 72%, >99:1 dr) as a white 
solid; mp 116-118 °C; νmax (ATR): 2976, 2360, 2322, 1726, 1448, 
1361, 1273, 1174; 
20
D
][α  −29.8 (c 0.50, CH2Cl2); 
1H NMR (500 
MHz, CD2Cl2) δH: 0.84 (3H, J 7.1, OCH2CH3), 3.13 (1H, dd, J 13.1, 
3.7, C(4)H), 3.79 (1H, d, J 3.79, C(5)H), 3.85 (2H, q, J 7.1, 
OCH2CH3), 4.02 (1H, d, J 13.1, C(3)H), 6.87 (2H, dd, J 7.3, 2.0, 
C(3)PhH), 7.24-7.28 (3H, m, C(3)PhH and C(6)PhH), 7.42-7.55 
(7H, m, PhH), 7.63-7.55 (1H, m, NSO2PhH), 7.85-7.90 (2H, m, 
NSO2PhH); 
13C{1H} NMR (126 MHz, CD2Cl2) δC: 13.9, 49.9, 51.1, 
62.2, 64.6, 70.0, 125.9, 128.8, 129.0, 129.2, 129.4, 129.6, 129.9 (2 × 
C), 134.2, 134.8, 136.5, 138.7, 169.9, 170.8; HRMS (ESI+): 
C24H25NO4SNa [M+Na]
+ found 446.1389, requires 446.1397 (−1.7 
ppm). 
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